Phase 4 N=34 Basic Science

Pharmacogenomics of Antiplatelet Response

Atherosclerosis

Bottom Line

View on ClinicalTrials.gov: NCT02234427 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jan 2017

Primary outcome: Primary: Differential Gene Expression — 77.1 FPKM for HBG1 Gene — p=<0.000005

Study Design & Population

Study type: Interventional
Phase: Phase 4
Interventions: Aspirin (Drug)
Age: Adult, Older Adult · 45+ yrs
Sex: All
Sponsor: Johns Hopkins University
Primary completion: Apr 2015

Outcome Measures

Outcome	Result	p-value
PRIMARY Differential Gene Expression	77.1	<0.000005 sig

Summary

This clinical trial will examine with effect of 2-week aspirin therapy on platelet gene expression in persons at high-risk of developing heart attacks due to family history of early-onset coronary artery disease

Eligibility Criteria

Inclusion Criteria

45-75 years
GeneSTAR participant
No personal History of Coronary Artery Disease
Women who are post-menopausal
Women who are using a reliable method of contraception, such as history of tubal ligation, IUD or taking OCP

Exclusion Criteria

Taking aspirin prescribed by physician
weight 160/95)
History of gastrointestinal ulcer/bleeding
Mental incompetence to make decision to participate.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02234427). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.